New drug therapies in peripheral T-cell lymphoma

References

• Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project. Ann. Oncol.9(7), 717–720 (1998).
   PubMed Web of Science ®Google Scholar
• Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J. Clin. Oncol.26(25), 4124–4130 (2008).
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Gutierrez A, Martinez-Delgado B, Perez-Manga G. Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets. Crit. Rev. Oncol. Hematol.71(3), 181–198 (2009).
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL et al.WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues (4th Edition). IARC, Lyon, France (2008).
   Google Scholar
• Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann. Oncol.15(10), 1467–1475 (2004).
   PubMed Web of Science ®Google Scholar
• Armitage J, Vose J, Weisenburger D. Towards understanding the peripheral T cell lymphomas. Ann. Oncol.15, 1447–1449 (2004).
   PubMed Web of Science ®Google Scholar
• Gascoyne RD, Aoun P, Wu D et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood93(11), 3913–3921 (1999).
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Gaulard P, Lepage E et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood92(1), 76–82 (1998).
   PubMed Web of Science ®Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S et al. A Phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin’s lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann. Oncol.5(Suppl. 2), 91–95 (1994).
   PubMed Web of Science ®Google Scholar
• Escalon MP, Liu NS, Yang Y et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the MD Anderson Cancer Center experience. Cancer103(10), 2091–2098 (2005).
   PubMed Web of Science ®Google Scholar
• Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood83(9), 2451–2458 (2005).
   Google Scholar
• Rassidakis GZ, Jones D, Lai R et al. BCL-2 family proteins in peripheral T-cell lymphomas: correlation with tumour apoptosis and proliferation. J. Pathol.200(2), 240–248 (2003).
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N. Engl. J. Med.333(23), 1540–1545 (1995).
   PubMed Web of Science ®Google Scholar
• d’Amore F, Relander T, Lauritzsen GF. Dose-dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remission in a large fraction of patients with previously untreated peripheral T-cell lymphoma (PTCLs) – overall and subtype-specific results of a Phase II study from the Nordic Lymphoma Group. Presented at: Annual Meeting of the European Haematology Association. Berlin, Germany, 4–6 June 2009.
   Google Scholar
• Reimer P, Rudiger T, Geissinger E et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J. Clin. Oncol.27(1), 106–113 (2009).
   PubMed Web of Science ®Google Scholar
• Corradini P, Dodero A, Zallio F et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin’s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J. Clin. Oncol.22(11), 2172–2176 (2004).
   PubMed Web of Science ®Google Scholar
• Horwitz SM. Novel therapies and role of transplant in the treatment of peripheral T-cell lymphomas. Hematology Am. Soc. Hematol. Educ. Program289–296 (2008).
   PubMedGoogle Scholar
• No authors listed. StatBite: FDA oncology drug product approvals in 2009. J. Natl Cancer Inst.102(4), 219 (2010).
   PubMedGoogle Scholar
• Sirotnak FM, DeGraw JI, Colwell WT, Piper JR. A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemother. Pharmacol.42(4), 313–318 (1998).
   PubMed Web of Science ®Google Scholar
• Wang ES, O’Connor O, She Y, Zelenetz AD, Sirotnak FM, Moore MA. Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk. Lymphoma44(6), 1027–1035 (2003).
   PubMed Web of Science ®Google Scholar
• O’Connor OA. Developing new drugs for the treatment of lymphoma. Eur. J. Haematol. Suppl.66, 150–158 (2005).
   Google Scholar
• O’Connor OA, Hamlin PA, Portlock C et al. Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br. J. Haematol.139(3), 425–428 (2007).
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Horwitz S, Hamlin P et al. Phase II–I–II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J. Clin. Oncol.27(26), 4357–4364 (2009).
   PubMed Web of Science ®Google Scholar
• Mould DR, Sweeney K, Duffull SB et al. A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin’s or Hodgkin’s lymphoma. Clin. Pharmacol. Ther.86(2), 190–196 (2009).
   PubMed Web of Science ®Google Scholar
• Pro B, Coiffier B, Horwitz SM et al. Correlation between baseline methylmalonic acid status and mucositis severity in the PROPEL study: implications for vitamin prophylaxis. ASH (Annual Meeting Abstracts)114(22), 1681 (2009).
   Google Scholar
• O’Connor O, Pro B, Pinter-Brown L et al. PROPEL: results of the pivotal, multicenter, Phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). J. Clin. Oncol. (Meeting Abstracts).27(15S), 8561 (2009).
   Google Scholar
• Pinter-Brown L, Horwitz SM, Pro B et al. Safety and management of pralatrexate treatment in relapsed or refractory peripheral T-cell lymphoma (PTCL). ASH (Annual Meeting Abstracts)114(22), 1675 (2009).
   Google Scholar
• Savage KJ, Shustov AR, Goy A et al. Pralatrexate induces responses in patients with highly refractory peripheral T-cell lymphoma (PTCL). ASH (Annual Meeting Abstracts)114(22), 1678 (2009).
   Google Scholar
• Marchi E, Paoluzzi L, Scotto L et al. Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Clin. Cancer Res.16(14), 3648–3658 (2010).
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Vose JM, Advani R et al. Pralatrexate and gemcitabine in patients with relapsed or refractory lymphoproliferative malignancies: Phase 1 results. ASH (Annual Meeting Abstracts)114(22), 1674 (2009).
   Google Scholar
• Horwitz SM, Vose JM, Advani R et al. A Phase 1/2A open-label study of pralatrexate and gemcitabine in patients with relapsed or refractory lymphoproliferative malignancies. ASH (Annual Meeting Abstracts)112(11), 1570 (2008).
   Google Scholar
• Jones LK, Saha V. Chromatin modification, leukaemia and implications for therapy. Br. J. Haematol.118(3), 714–727 (2002).
   PubMed Web of Science ®Google Scholar
• Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer1(3), 194–202 (2001).
   PubMed Web of Science ®Google Scholar
• Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell4(1), 13–18 (2003).
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov.5(9), 769–784 (2006).
   PubMed Web of Science ®Google Scholar
• Richon V. Mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br. J. Cancer95, S2–S6 (2006).
   Web of Science ®Google Scholar
• Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J. Clin. Oncol.23(17), 3971–3993 (2005).
   PubMed Web of Science ®Google Scholar
• Schrump DS. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin. Cancer Res.15(12), 3947–3957 (2009).
   PubMed Web of Science ®Google Scholar
• Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin. Cancer Res.15(12), 3958–3969 (2009).
   PubMed Web of Science ®Google Scholar
• Rasheed W, Bishton M, Johnstone RW, Prince HM. Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev. Anticancer Ther.8(3), 413–432 (2008).
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Bates SE. Epigenetic modifiers: basic understanding and clinical development. Clin. Cancer Res.15(12), 3918–3926 (2009).
   PubMed Web of Science ®Google Scholar
• Shah MH, Binkley P, Chan K et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin. Cancer Res.12(13), 3997–4003 (2006).
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye AR, Wright JJ et al. Cardiac studies in patients treated with depsipeptide, FK228, in a Phase II trial for T-cell lymphoma. Clin. Cancer Res.12(12), 3762–3773 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang QL, Wang L, Zhang YW et al. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Leukemia23(8), 1507–1514 (2009).
   PubMed Web of Science ®Google Scholar
• Heider U, Rademacher J, Lamottke B et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. Eur. J. Haematol.82(6), 440–449 (2009).
   PubMed Web of Science ®Google Scholar
• Kelly WK, O’Connor OA, Krug LM et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol.23(17), 3923–3931 (2005).
   PubMed Web of Science ®Google Scholar
• Kelly WK, Richon VM, O’Connor O et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res.9(10 Pt 1), 3578–3588 (2003).
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Heaney ML, Schwartz L et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol.24(1), 166–173 (2006).
   PubMed Web of Science ®Google Scholar
• Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist12(10), 1247–1252 (2007).
   PubMed Web of Science ®Google Scholar
• Duvic M, Talpur R, Ni X et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood109(1), 31–39 (2007).
   PubMed Web of Science ®Google Scholar
• Olsen EA, Kim YH, Kuzel TM et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol.25(21), 3109–3115 (2007).
   PubMed Web of Science ®Google Scholar
• Mann BS, Johnson JR, He K et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin. Cancer Res.13(8), 2318–2322 (2007).
   PubMed Web of Science ®Google Scholar
• Furumai R, Matsuyama A, Kobashi N et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res.62(17), 4916–4921 (2002).
   PubMed Web of Science ®Google Scholar
• Woo S, Gardner ER, Chen X et al. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin. Cancer Res.15(4), 1496–1503 (2009).
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Robey R, Sandor V et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood98(9), 2865–2868 (2001).
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Turner M et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J. Clin. Oncol.27(32), 5410–5417 (2009).
   PubMed Web of Science ®Google Scholar
• Bates S, Piekarz R, Wright J et al. Final clinical results of a Phase 2 NCI multicenter study of romidepsin in recurrent cutaneous T-cell lymphoma (molecular analyses included). ASH (Annual Meeting Abstracts)112(11), 1568 (2008).
   Google Scholar
• Whittaker SJ, Demierre MF, Kim EJ et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J. Clin. Oncol.28(29), 4485–4491 (2010).
   PubMed Web of Science ®Google Scholar
• Piekarz R, Wright J, Frye R et al. Final results of a Phase 2 NCI multicenter study of romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL). ASH (Annual Meeting Abstracts)114(22), 1657 (2009).
   Google Scholar
• Piekarz RL, Frye R, Prince HM. Phase II trial of romidepsin in patients with peripheral T-cell lymphoma. Blood DOI: 10.1182/blood-2010-10-312603 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Coiffier B, Pro B, Prince HM et al. Final results from a pivotal, multicenter, international, open-label, Phase 2 study of romidepsin in progressive or relapsed peripheral T-cell lymphoma (PTCL) following prior systemic therapy. ASH (Annual Meeting Abstracts)116(21), 114 (2010).
   Google Scholar
• Ellis L, Pan Y, Smyth GK et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin. Cancer Res.14(14), 4500–4510 (2008).
   PubMed Web of Science ®Google Scholar
• Duvic M, Becker JC, Dalle S et al. Phase II trial of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma (CTCL). ASH (Annual Meeting Abstracts)112(11), 1005 (2008).
   Google Scholar
• Ottmann OG, Spencer A, Prince HM et al. Phase IA/II study of oral panobinostat (LBH589), a novel pan-deacetylase inhibitor (DACi) demonstrating efficacy in patients with advanced hematologic malignancies. ASH (Annual Meeting Abstracts)112(11), 958 (2008).
   Google Scholar
• Zain JM, O’Connor O, Zinzani PL, Norman A, de Nully Brown P. Multicenter, open-label trial of PXD 101 in patients with relapsed/refractory peripheral T-cell lymphoma. J. Clin. Oncol. (Meeting Abstracts).28(15 Suppl.), e18565 (2010).
   Google Scholar
• Robak T, Lech-Maranda E, Korycka A, Robak E. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Curr. Med. Chem.13(26), 3165–3189 (2006).
   PubMed Web of Science ®Google Scholar
• Sallah S, Wan JY, Nguyen NP. Treatment of refractory T-cell malignancies using gemcitabine. Br. J. Haematol.113(1), 185–187 (2001).
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Venturini F, Stefoni V et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann. Oncol.21(4), 860–863 (2010).
   PubMed Web of Science ®Google Scholar
• Kim JG, Sohn SK, Chae YS et al. CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother. Pharmacol.58(1), 35–39 (2006).
   PubMed Web of Science ®Google Scholar
• Emmanouilides C, Colovos C, Pinter-Brown L et al. Pilot study of fixed-infusion rate gemcitabine with cisplatin and dexamethasone in patients with relapsed or refractory lymphoma. Clin. lymp.5(1), 45–49 (2004).
   PubMedGoogle Scholar
• Arkenau HT, Chong G, Cunningham D et al. Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica92(2), 271–272 (2007).
   PubMed Web of Science ®Google Scholar
• Spencer A, Reed K, Arthur C. Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim. Int. Med. J.37(11), 760–766 (2007).
   Google Scholar
• Marchi E, Paoluzzi L, Venkatraman SE, O’Connor OA. Pralatrexate (PDX) compliments the activity of the proteasome inhibitor bortezomib (B) in in vitro models of lymphoid T-cell malignancies. Blood ASH (Annual Meeting Abstracts)112 (2008) (Abstract 3619).
   Google Scholar
• Kicska GA, Long L, Horig H et al. Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes. Proc. Natl Acad. Sci. USA98(8), 4593–4598 (2001).
   PubMed Web of Science ®Google Scholar
• Furman RR, Gore L, Ravandi F, Hoelzer D. Forodesine IV (Bcx-1777) is clinically active in relapsed/refractory T-cell leukemia: results of a Phase II study (interim report). ASH (Annual Meeting Abstracts)108(11), 1851 (2006).
   Google Scholar
• Duvic M, Forero-Torres A, Foss F, Olsen E, Kim Y. Response to oral forodesine in refractory cutaneous T-cell lymphoma: interim results of a Phase I/II study. ASH (Annual Meeting Abstracts)110(11), 122 (2007).
   Google Scholar
• Duvic M, Forero-Torres A, Foss F, Olsen E, Pinter-Brown L, Kim Y. Long-term treatment of CTCL with the oral PNP inhibitor, forodesine. J. Clin. Oncol. (Meeting Abstracts)27(15S), 8552 (2009).
   Google Scholar
• Robak T, Korycka A, Lech-Maranda E, Robak P. Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. Molecules14(3), 1183–1226 (2009).
   PubMed Web of Science ®Google Scholar
• Berg SL, Blaney SM, Devidas M et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children’s Oncology Group. J. Clin. Oncol.23(15), 3376–3382 (2005).
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Porcu P, Johnson J et al. Results of a Phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Leuk. Lymphoma48(1), 97–103 (2007).
   PubMed Web of Science ®Google Scholar
• Mulford DA, Pohlman BL, Hamlin PA, Young F, Pamer E, Horwitz SM. A Phase I/II trial of clofarabine in patients with relapsed T-cell or NK-cell lymphomas. J. Clin. Oncol. (Meeting Abstracts)28(15 Suppl.), 8046 (2010).
   Google Scholar
• Schmitz N, Trumper L, Ziepert M et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Blood116(18), 3418–3425 (2010).
   PubMed Web of Science ®Google Scholar
• Salisbury JR, Rapson NT, Codd JD, Rogers MV, Nethersell AB. Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin’s lymphomas. J. Clin. Pathol.47(4), 313–317 (1994).
   PubMed Web of Science ®Google Scholar
• Ginaldi L, De Martinis M, Matutes E et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk. Res.22(2), 185–191 (1998).
   PubMed Web of Science ®Google Scholar
• Dearden CE, Matutes E, Cazin B et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood98(6), 1721–1726 (2001).
   PubMed Web of Science ®Google Scholar
• Lundin J, Hagberg H, Repp R et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood101(11), 4267–4272 (2003).
   PubMed Web of Science ®Google Scholar
• Kennedy GA, Seymour JF, Wolf M et al. Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. Eur. J. Haematol.71(4), 250–256 (2003).
   PubMed Web of Science ®Google Scholar
• Enblad G, Hagberg H, Erlanson M et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood103(8), 2920–2924 (2004).
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim K, Kim BS et al. Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a Phase II prospective study. Ann. Oncol.20(2), 390–392 (2009).
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Alinari L, Tani M, Fina M, Pileri S, Baccarani M. Preliminary observations of a Phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica90(5), 702–703 (2005).
   PubMed Web of Science ®Google Scholar
• Gallamini A, Zaja F, Patti C et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood110(7), 2316–2323 (2007).
   PubMed Web of Science ®Google Scholar
• Kim JG, Sohn SK, Chae YS et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a Phase II study. Cancer Chemother. Pharmacol.60(1), 129–134 (2007).
   PubMed Web of Science ®Google Scholar
• Geissinger E, Bonzheim I, Roth S, Rosenwald A, Muller-Hermelink HK, Rudiger T. CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies. Leuk. Lymphoma50(6), 1010–1016 (2009).
   PubMed Web of Science ®Google Scholar
• Jiang L, Yuan CM, Hubacheck J et al. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br. J. Haematol.145(2), 173–179 (2009).
   PubMed Web of Science ®Google Scholar
• Amengual JE, Raphael BG. Sustained, durable responses with alemtuzumab in refractory angioimmunoblastic T-cell lymphoma. Leuk. Lymphoma51(7), 1347–1350 (2010).
   PubMed Web of Science ®Google Scholar
• Halene S, Zieske A, Berliner N. Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab. Nat. Clin. Pract. Oncol.3(3), 165–168; quiz 169 (2006).
   PubMedGoogle Scholar
• Villadsen LS, Skov L, Dam TN et al.In situ depletion of CD4+ T cells in human skin by zanolimumab. Arch. Dermatol. Res.298(9), 449–455 (2007).
   PubMed Web of Science ®Google Scholar
• Kim YH, Duvic M, Obitz E et al. Clinical efficacy of zanolimumab (HuMax-CD4), two Phase 2 studies in refractory cutaneous T-cell lymphoma. Blood109(11), 4655–4662 (2007).
   PubMed Web of Science ®Google Scholar
• Mestel DS, Beyer M, Mobs M, Steinhoff M, Sterry W, Assaf C. Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sezary syndrome. Expert Opin. Biol. Ther.8(12), 1929–1939 (2008).
   PubMed Web of Science ®Google Scholar
• d’Amore F, Radford J, Relander T et al. Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. Br. J. Haematol.150(5), 565–573 (2010).
   PubMed Web of Science ®Google Scholar
• O’Mahony D, Morris JC, Moses L et al. Phase I trial of siplizumab in CD2-positive lymphoproliferative disease. ASH (Annual Meeting Abstracts)106(11), 3353 (2005).
   Google Scholar
• O’Mahony D, Morris JC, Stetler-Stevenson M et al. EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. Clin. Cancer Res.15(7), 2514–2522 (2009).
   PubMed Web of Science ®Google Scholar
• Waters CA, Schimke PA, Snider CE et al. Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells. Eur. J. Immunol.20(4), 785–791 (1990).
   PubMed Web of Science ®Google Scholar
• Prince HM, Duvic M, Martin A et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J. Clin. Oncol.28(11), 1870–1877 (2010).
   PubMed Web of Science ®Google Scholar
• Foss F, Duvic M, Geskin L et al. Efficacy and safety of denileukin diftitox (Ontak®) in the treatment of cutaneous T-cell lymphoma (CTCL) according to CD25 status. Blood (ASH Annual Meeting Abstracts)108 (2006) (Abstract 2712).
   Google Scholar
• Dang NH, Pro B, Hagemeister FB et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br. J. Haematol.136(3), 439–447 (2007).
   PubMed Web of Science ®Google Scholar
• Foss FM, Sjak-Shie NN, Goy A, Advani R, Jacobsen ED. Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial. ASCO Meeting Abstracts28(15 Suppl.), 8045 (2010).
   Google Scholar
• Mitra-Kaushik S, Harding JC, Hess JL, Ratner L. Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants. Blood104(3), 802–809 (2004).
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Musuraca G, Tani M et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J. Clin. Oncol.25(27), 4293–4297 (2007).
   PubMed Web of Science ®Google Scholar
• Lee J, Suh C, Kang HJ et al. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Ann. Oncol.19(12), 2079–2083 (2008).
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Voorhees PM, Garcia RA et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood105(8), 3058–3065 (2005).
   PubMed Web of Science ®Google Scholar
• Delmer A, Fitoussi O, Gaulard P et al. A Phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: results of the GELA LNH05-1T trial. ASCO Meeting Abstracts.27(15S), 8554 (2009).
   Google Scholar
• Dueck G, Chua N, Prasad A et al. Interim report of a Phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer116(19), 4541–4548 (2010).
   PubMed Web of Science ®Google Scholar
• Hess G, Smith SM, Berkenblit A, Coiffier B. Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin. Oncol.36(Suppl. 3), S37–S45 (2009).
   PubMedGoogle Scholar
• Ansell SM, Tang H, Kurtin P et al. A Phase II Study of temsirolimus (CCI-779) in combination with rituximab in patients with relapsed or refractory mantle cell lymphoma. ASH (Annual Meeting Abstracts)114(22), 1665 (2009).
   Google Scholar
• Johnston PB, Ansell SM, Colgan JP et al. mTOR inhibition for relapsed or refractory Hodgkin lymphoma: promising single agent activity with everolimus (RAD001). ASH (Annual Meeting Abstracts)110(11), 2555 (2007).
   Google Scholar
• Guenther A, Baumann P, Burger R, Klapper W, Schmidmaier R, Gramatzki M. Phase I/II study with single agent everolimus (RAD001) in patients with relapsed or refractory multiple myeloma. ASH (Annual Meeting Abstracts)114(22), 3850 (2009).
   Google Scholar
• Yee KW, Zeng Z, Konopleva M et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res.12(17), 5165–5173 (2006).
   PubMed Web of Science ®Google Scholar
• Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res.15(4), 1126–1132 (2009).
   PubMed Web of Science ®Google Scholar
• Jung JT, Kim DH, Kwak EK et al. Clinical role of Bcl-2, Bax, or p53 overexpression in peripheral T-cell lymphomas. Ann. Hematol.85(9), 575–581 (2006).
   PubMed Web of Science ®Google Scholar
• Wilson W, O’Connor OO, Roberts AW et al. ABT-263 activity and safety in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). J. Clin. Oncol. (Meeting Abstracts)27(15S), 8574 (2009).
   Google Scholar
• Wilson WH, O’Connor OA, Czuczman MS et al. Phase 1/2a Study of ABT-263 in relapsed or refractory lymphoid malignancies. ASH (Annual Meeting Abstracts)114(22), 1711 (2009).
   Google Scholar
• Anagnostopoulos I, Hummel M, Finn T et al. Heterogeneous Epstein–Barr virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type. Blood80(7), 1804–1812 (1992).
   PubMed Web of Science ®Google Scholar
• Attygalle AD, Chuang SS, Diss TC, Du MQ, Isaacson PG, Dogan A. Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics. Histopathology50(4), 498–508 (2007).
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Wilson WH. Angioimmunoblastic T-cell lymphoma: immune modulation as a therapeutic strategy. Leuk. Lymphoma48(3), 449–451 (2007).
   PubMed Web of Science ®Google Scholar
• de Leval L, Gisselbrecht C, Gaulard P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br. J. Haematol.148(5), 673–689 (2010).
   PubMed Web of Science ®Google Scholar
• Iannitto E, Ferreri AJ, Minardi V, Tripodo C, Kreipe HH. Angioimmunoblastic T-cell lymphoma. Crit. Rev. Oncol. Hematol.68(3), 264–271 (2008).
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Advani RH. Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies. Clin. Adv. Hematol. Oncol.6(12), 899–909 (2008).
   PubMedGoogle Scholar
• Mourad N, Mounier N, Briere J et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials. Blood111(9), 4463–4470 (2008).
   PubMed Web of Science ®Google Scholar
• Advani R, Horwitz S, Zelenetz A, Horning SJ. Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. Leuk. Lymphoma48(3), 521–525 (2007).
   PubMed Web of Science ®Google Scholar
• Joly B, Plonquet A, Grare M et al. Rituximab in combination with CHOP regimen in angioimmunoblastic T-cell lymphoma: results of the Phase II RAIL trial – a prospective study of the Groupe d’Etude des Lymphomes de l’Adulte (GELA). J. Clin. Oncol. (Meeting Abstracts)28(15 Suppl.), (2010).
   Google Scholar
• Bruns I, Fox F, Reinecke P et al. Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. Leukemia19(11), 1993–1995 (2005).
   PubMed Web of Science ®Google Scholar
• Aguiar Bujanda D. Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab. Ann. Oncol.19(2), 396–397 (2008).
   PubMed Web of Science ®Google Scholar
• Advani RH, Hong F, Ganjoo KN et al. Cardiac toxicity associated with the anti-VEGF monoclonal antibody bevacizumab (Avastin) in combination with CHOP (A-CHOP) chemotherapy for peripheral T cell lymphoma (PTCL): the ECOG 2404 trial. ASH (Annual Meeting Abstracts)114(22), 1671 (2009).
   Google Scholar
• Gottardi M, Danesin C, Canal F et al. Complete remission induced by thalidomide in a case of angioimmunoblastic T-cell lymphoma refractory to autologous stem cell transplantation. Leuk. Lymphoma49(9), 1836–1838 (2008).
   PubMed Web of Science ®Google Scholar
• Ramasamy K, Lim Z, Pagliuca A. Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone. Haematologica91(8 Suppl.), ECR44 (2006).
   PubMed Web of Science ®Google Scholar
• Dogan A, Ngu LS, Ng SH, Cervi PL. Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide. Leukemia19(5), 873–875 (2005).
   PubMed Web of Science ®Google Scholar
• Strupp C, Aivado M, Germing U, Gattermann N, Haas R. Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: two case reports. Leuk. Lymphoma43(1), 133–137 (2002).
   PubMed Web of Science ®Google Scholar
• Stein H, Foss HD, Durkop H et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood96(12), 3681–3695 (2000).
   PubMed Web of Science ®Google Scholar
• Sandlund JT, Pui CH, Roberts WM et al. Clinicopathologic features and treatment outcome of children with large-cell lymphoma and the t(2;5)(p23;q35). Blood84(8), 2467–2471 (1994).
   PubMed Web of Science ®Google Scholar
• Webb TR, Slavish J, George RE et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev. Anticancer Ther.9(3), 331–356 (2009).
   PubMed Web of Science ®Google Scholar
• Falini B, Pulford K, Pucciarini A et al. Lymphomas expressing ALK fusion protein(s) other than NPM–ALK. Blood94(10), 3509–3515 (1999).
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Leonard JP, Younes A et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br. J. Haematol.146(2), 171–179 (2009).
   PubMed Web of Science ®Google Scholar
• Blum KA, Johnson JL, Jung SH, Cheson BD, Bartlett NL. Serious pulmonary toxicity with SGN-30 and gemcitabine, vinorelbine, and liposomal doxorubicin in patients with relapsed/refractory Hodgkin lymphoma (HL): cancer and leukemia group B (CALGB) 50502. Blood (ASH Annual Meeting Abstracts)112 (2008) (Abstract 232).
   Google Scholar
• Ansell SM, Horwitz SM, Engert A et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large-cell lymphoma. J. Clin. Oncol.25(19), 2764–2769 (2007).
   PubMed Web of Science ®Google Scholar
• Younes A, Zalevsky J, Blum KA et al. Evaluation of the pharmacokinetics, immunogenicity, and safety of XmAb®2513 in the ongoing study XmAb2513–01: a Phase 1 study of every other week XmAb2513 to evaluate the safety, tolerability, and pharmacokinetics in patients with Hodgkin lymphoma or anaplastic large cell lymphoma. Blood (ASH Annual Meeting Abstracts)112 (2008) (Abstract 5012).
   Google Scholar
• Hamblett KJ, Barton J, Cerveny CG et al. SGN-35, an Anti-CD30 Antibody–drug conjugate, exhibits potent antitumor activity for the treatment of CD30+ Malignancies. Blood (ASH Annual Meeting Abstracts)106 (2005) (Abstract 610).
   Google Scholar
• Younes A, Bartlett NL, Leonard JP et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med.363(19), 1812–1821 (2010).
   PubMed Web of Science ®Google Scholar
• Shustov AR, Advani R, Brice P et al. Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma. ASH (Annual Meeting Abstracts)116(21), 961 (2010).
   Google Scholar
• Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med.363(18), 1693–1703 (2010).
   PubMed Web of Science ®Google Scholar
• Au WY, Weisenburger DD, Intragumtornchai T et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-cell Lymphoma Project. Blood113(17), 3931–3937 (2009).
   PubMed Web of Science ®Google Scholar
• Li YX, Yao B, Jin J et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J. Clin. Oncol.24(1), 181–189 (2006).
   PubMed Web of Science ®Google Scholar
• You JY, Chi KH, Yang MH et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann. Oncol.15(4), 618–625 (2004).
   PubMed Web of Science ®Google Scholar
• Yong W, Zheng W, Zhu J et al.L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Ann. Hematol.88(7), 647–652 (2009).
   PubMed Web of Science ®Google Scholar
• Jaccard A, Gachard N, Marin B et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a Phase II study. Blood117(6), 1834–1839 (2010).
   PubMed Web of Science ®Google Scholar